Acacia Pharma wins BEL Small Company of the Year Award 2019 - Gilde Healthcare

Acacia Pharma wins BEL Small Company of the Year Award 2019

January 24, 2020

Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare portfolio company Acacia Pharma Group plc (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, has been awarded BEL Small Company of the Year 2019 by Euronext Brussels at its annual New Year’s Ceremony held in Brussels last night. The annual ceremony recognises the best performing companies in Belgium and is attended by 600 key stakeholders. BEL Small Company of the Year is awarded to the small cap company that has demonstrated the highest relative increase in market capitalisation. The award was presented by the Prime Minister of Belgium, Sophie Wilmès.
 
Mike Bolinder, CEO of Acacia Pharma:

“We are delighted with this Award which is a tangible recognition of our active growth strategy. In 2019, we have been finalizing our commercial strategy and infrastructure ahead of a number of key milestones expected during the first half of 2020. Regulatory decisions to approve two product candidates for marketing in the US, BARHEMSYS® and ByFavo™, are expected by 26 February and 5 April, respectively. These products address important unmet needs in the treatment and care of patients undergoing invasive medical procedures. Our US team is now preparing to commercialise these products, pending approval, and we are confident in the benefits and value they will bring to patients, healthcare providers and shareholders alike. We are looking forward to 2020, which is expected to be an exciting and transformational year for Acacia Pharma.”

About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
The Group’s lead project, BARHEMSYS® (intravenous amisulpride) for post-operative nausea & vomiting (PONV), has generated positive results in four Phase 3 clinical studies. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV), has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma is based in Cambridge, UK and Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH. For more information, visit the company’s website at www.acaciapharma.com.

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing over €1 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in medtech, digital health and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
February 29, 2024

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent...
February 28, 2024

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125...
February 27, 2024